FDA will issue a formal public communication cautioning against extrapolating single-case psilocybin reports to clinical practice by Q1 2027

A few viral stories online claim psilocybin cured someone's Alzheimer's disease. When enough people see these stories, patients and doctors start asking for the treatment, even though one person getting better doesn't prove it works. The FDA (the US drug regulator) will probably issue a formal warning telling doctors and patients not to believe these individual stories. This matters because it protects people from trying unproven treatments.

Viral single-case 'miracle cure' narratives — particularly in neurodegeneration — have historically triggered FDA MedWatch alerts or public statements within 6–9 months when they generate patient demand or provider confusion. The Alzheimer's psilocybin case report dynamic fits this pattern precisely. Falsifiable: an FDA Dear Healthcare Provider letter, MedWatch safety communication, or formal press statement on psilocybin/Alzheimer's extrapolation issued by Feb 28, 2027 resolves YES. Absence of any such communication resolves NO.